A Randomized Active-Controlled Study Comparing the Efficacy and Safety of Vernakalant to Amiodarone in Recent-Onset Atrial Fibrillation

被引:236
作者
Camm, A. John [1 ]
Capucci, Alessandro [2 ]
Hohnloser, Stefan H. [4 ]
Torp-Pedersen, Christian [3 ]
Van Gelder, Isabelle C. [5 ,6 ]
Mangal, Brian [7 ]
Beatch, Gregory [7 ]
机构
[1] St Georges Univ London, London SW17 0RE, England
[2] Univ Politecn Marche, Clin Cardiol, Ancona, Italy
[3] Univ Copenhagen, Hellerup, Denmark
[4] Goethe Univ Frankfurt, Frankfurt, Germany
[5] Univ Groningen, Univ Med Ctr Groningen, Groningen, Netherlands
[6] Interuniv Cardiol Inst Netherlands, Utrecht, Netherlands
[7] Cardiome Pharma Corp, Vancouver, BC, Canada
关键词
atrial fibrillation; amiodarone; antiarrhythmics; cardioversion; vernakalant; RAPID CONVERSION; INTRAVENOUS PROCAINAMIDE; ANTIARRHYTHMIC AGENT; SINUS RHYTHM; IBUTILIDE; PROPAFENONE; FLUTTER; CARDIOVERSION; FLECAINIDE; MANAGEMENT;
D O I
10.1016/j.jacc.2010.07.046
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives This randomized double-blind study compared the efficacy and safety of intravenous vernakalant and amiodarone for the acute conversion of recent-onset atrial fibrillation (AF). Background Intravenous vernakalant has effectively converted recent-onset AF and was well tolerated in placebo-controlled studies. Methods A total of 254 adult patients with AF (3 to 48 h duration) eligible for cardioversion were enrolled in the study. Patients received either a 10-min infusion of vernakalant (3 mg/kg) followed by a 15-min observation period and a second 10-min infusion (2 mg/kg) if still in AF, plus a sham amiodarone infusion, or a 60-min infusion of amiodarone (5 mg/kg) followed by a maintenance infusion (50 mg) over an additional 60 min, plus a sham vernakalant infusion. Results Conversion from AF to sinus rhythm within the first 90 min (primary end point) was achieved in 60 of 116 (51.7%) vernakalant patients compared with 6 of 116 (5.2%) amiodarone patients (p < 0.0001). Vernakalant resulted in rapid conversion (median time of 11 min in responders) and was associated with a higher rate of symptom relief compared with amiodarone (53.4% of vernakalant patients reported no AF symptoms at 90 min compared with 32.8% of amiodarone patients; p = 0.0012). Serious adverse events or events leading to discontinuation of study drug were uncommon. There were no cases of torsades de pointes, ventricular fibrillation, or polymorphic or sustained ventricular tachycardia. Conclusions Vernakalant demonstrated efficacy superior to amiodarone for acute conversion of recent-onset AF. Both vernakalant and amiodarone were safe and well tolerated in this study. (A Phase III Superiority Study of Vernakalant vs Amiodarone in Subjects With Recent Onset Atrial Fibrillation [AVRO]; NCT00668759) (J Am Coll Cardiol 2011;57:313-21) (C) 2011 by the American College of Cardiology Foundation
引用
收藏
页码:313 / 321
页数:9
相关论文
共 26 条
[11]   A comparative study of the efficacy and safety of Procainamide versus Propafenone versus Amiodarone for the conversion of recent-onset atrial fibrillation [J].
Kochiadakis, George E. ;
Igoumenidis, Nikos E. ;
Hamilos, Michail E. ;
Marketou, Maria E. ;
Chlouverakis, Gregory I. ;
Vardas, Panos E. .
AMERICAN JOURNAL OF CARDIOLOGY, 2007, 99 (12) :1721-1725
[12]   Vernakalant Hydrochloride for the Rapid Conversion of Atrial Fibrillation After Cardiac Surgery A Randomized, Double-Blind, Placebo-Controlled Trial [J].
Kowey, Peter R. ;
Dorian, Paul ;
Mitchell, L. Brent ;
Pratt, Craig M. ;
Roy, Denis ;
Schwartz, Peter J. ;
Sadowski, Jerzy ;
Sobczyk, Dorota ;
Bochenek, Andrzej ;
Toft, Egon .
CIRCULATION-ARRHYTHMIA AND ELECTROPHYSIOLOGY, 2009, 2 (06) :652-659
[13]   Acute treatment of atrial fibrillation [J].
Kowey, PR ;
Marinchak, RA ;
Rials, SJ ;
Filart, RA .
AMERICAN JOURNAL OF CARDIOLOGY, 1998, 81 (5A) :16C-22C
[14]   Evaluation and management of atrial fibrillation in the emergency department [J].
Li, HG ;
Easley, A ;
Barrington, W ;
Windle, J .
EMERGENCY MEDICINE CLINICS OF NORTH AMERICA, 1998, 16 (02) :389-+
[15]   Comparison of intravenous flecainide, propafenone, and amiodarone for conversion of acute atrial fibrillation to sinus rhythm [J].
Martínez-Marcos, FJ ;
García-Garmendia, JL ;
Ortega-Carpio, A ;
Fernández-Gómez, JM ;
Santos, JM ;
Camacho, C .
AMERICAN JOURNAL OF CARDIOLOGY, 2000, 86 (09) :950-953
[16]   Flecainide versus ibutilide for immediate cardioversion of atrial fibrillation of recent onset [J].
Reisinger, J ;
Gatterer, E ;
Lang, W ;
Vanicek, T ;
Eisserer, G ;
Bachleitner, T ;
Niemeth, C ;
Aicher, F ;
Grander, W ;
Heinze, G ;
Kühn, P ;
Siostrzonek, P .
EUROPEAN HEART JOURNAL, 2004, 25 (15) :1318-1324
[17]   A randomized, controlled trial of RSD1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillation [J].
Roy, D ;
Rowe, BH ;
Stiell, IG ;
Coutu, B ;
Ip, JH ;
Phaneuf, D ;
Lee, J ;
Vidaillet, H ;
Dickinson, G ;
Grant, S ;
Ezrin, AM ;
Beatch, GN .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2004, 44 (12) :2355-2361
[18]   Vernakalant hydrochloride for rapid conversion of atrial fibrillation - A phase 3, randomized, placebo-controlled trial [J].
Roy, Denis ;
Pratt, Craig M. ;
Torp-Pedersen, Christian ;
Wyse, D. George ;
Toft, Egon ;
Juul-Moller, Steen ;
Nielsen, Tonny ;
Rasmussen, S. Lind ;
Stiell, Ian G. ;
Coutu, Benoit ;
Ip, John H. ;
Pritchett, Edward L. C. ;
Camm, A. John .
CIRCULATION, 2008, 117 (12) :1518-1525
[19]  
Siddoway LA, 2003, AM FAM PHYSICIAN, V68, P2189
[20]   Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation [J].
Stambler, BS ;
Wood, MA ;
Ellenbogen, KA ;
Perry, KT ;
Wakefield, LK ;
VanderLugt, JT ;
AbiSamra, FM ;
Ahern, TS ;
Burger, AJ ;
Cassidy, DM ;
Denker, ST ;
DiMarco, JP ;
Flowers, NC ;
Sridharan, R ;
Hessen, SH ;
Kalbfleisch, JM ;
Kowey, PR ;
Mattioni, TA ;
Meissner, MD ;
Portnow, AS ;
Stratton, SS ;
Sager, PT ;
Sharma, AD ;
Wesley, RC ;
Windle, JR ;
Zoble, RG .
CIRCULATION, 1996, 94 (07) :1613-1621